Disitamab Vedotin

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 00:59:50 GMT 2025` Edited by `admin` on `Wed Apr 02 00:59:50 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	RB3U3A1S27
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

\Immunoglobulin G1, anti-(human tyrosine kinase receptor ErbB2) (human-Mus musculus monoclonal RC48-270A4023 ?1-chain), disulfide with human-Mus musculus monoclonal RC48-270A4023 ?-chain, dimer, thioether with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrol

Preferred Name

English

Disitamab Vedotin

Official Name

English

DISITAMAB VEDOTIN [USAN]

Common Name

English

Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain hu

Common Name

English

RC48-ADC

Code

English

Disitamab Vedotin [WHO-DD]

Common Name

English

disitamab vedotin [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

649418

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

Code System Code Type Description

SMS_ID

300000005885

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

PRIMARY

USAN

MN-186

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

PRIMARY

CAS

2136633-23-1

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

PRIMARY

NCI_THESAURUS

C169918

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

PRIMARY

INN

10933

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

PRIMARY

FDA UNII

RB3U3A1S27

Created by admin on Wed Apr 02 00:59:50 GMT 2025 , Edited by admin on Wed Apr 02 00:59:50 GMT 2025

PRIMARY

From	To
1_22	1_96
1_142	1_198
1_218	3_212
1_224	2_224
1_227	2_227
1_259	1_319
1_365	1_423
2_22	2_96
2_142	2_198
2_218	4_212
2_259	2_319
2_365	2_423
3_23	3_88
3_132	3_192
4_23	4_88
4_132	4_192

Glycosylation Link Type	Site
N	1_295
N	2_295

Related Record Type Details


					474FJM6Y9C

Disitamab

PARENT -> CONJUGATE

Amount:


					V7I58RC5EJ

MONOMETHYL AURISTATIN E

TOXIN -> CONJUGATE

Amount:


					7J9Y28299R

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2

TARGET->CONJUGATED TOXIN

Amount:

Related Record Type Details


					RB3U3A1S27

Disitamab Vedotin

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_218] [1_224] [1_227] [2_218] [2_224] [2_227] [3_212] [4_212]	SITE_SPECIFIC		Amount:	Cysteinyl vedotin	6603L01WUR

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL